Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210)
Article first published online: 11 FEB 2013
Copyright © 2013 Wiley Periodicals, Inc.
Journal of Surgical Oncology
Volume 107, Issue 7, pages 741–745, 1 June 2013
How to Cite
Iwasaki, Y., Sasako, M., Yamamoto, S., Nakamura, K., Sano, T., Katai, H., Tsujinaka, T., Nashimoto, A., Fukushima, N., Tsuburaya, A. and on behalf of the Gastric Cancer Surgical Study Group of the Japan Clinical Oncology Group (2013), Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210). J. Surg. Oncol., 107: 741–745. doi: 10.1002/jso.23301
- Issue published online: 25 MAY 2013
- Article first published online: 11 FEB 2013
- Manuscript Accepted: 12 NOV 2012
- Manuscript Received: 26 APR 2012
- Ministry of Health, Labour and Welfare of Japan. Grant Numbers: 14S-3, 14S-4, H13-Gan-014
- gastric cancer;
- preoperative chemotherapy;
- type 4 gastric cancer;
- linitis plastica;
- type 3 gastric cancer
Background and Objectives
We conducted a phase II study to evaluate the safety and efficacy of preoperative chemotherapy with S-1 + cisplatin followed by gastrectomy in patients with linitis plastica (type 4) or large ulcero-invasive-type (type 3) gastric cancer.
Eligibility criteria included histologically proven adenocarcinoma of the stomach; clinically resectable gastric cancer of type 4 or type 3. Patients received two 28-day courses of preoperative chemotherapy of S-1 (80–120 mg/body, p.o., days 1–21) and cisplatin (CDDP; 60 mg/m2, i.v., day 8). Primary endpoints were completion of protocol treatment and incidence of treatment-related death (TRD).
Among the 49 eligible patients with the median age of 61 years, 36 completed the protocol treatment comprising two courses of preoperative chemotherapy and R0/1 resection (73.5% completion, 80% CI, 63.7–81.7%). One TRD was observed during the first course of chemotherapy. Median survival and 3-year overall survival were 17.3 months and 24.5%, respectively.
Preoperative chemotherapy with S-1 + CDDP followed by gastrectomy is a safe and promising treatment for type 4 and large type 3 gastric cancers. Based on the results of this study, we are now conducting a phase III study (JCOG0501) to confirm the superiority of this treatment. J. Surg. Oncol. 2013;107:741–745. © 2013 Wiley Periodicals, Inc.